Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling.

Zhang G, Wang X, Wang Y, Liu H, Xie Q, Li X, Xu M, Zhou L

DOI: 10.1093/jpp/rgag139
Published: 2026 Nov 4
Container: The Journal of pharmacy and pharmacology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jpp/rgag139,
  title = {Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling.},
  author = {Zhang G and Wang X and Wang Y and Liu H and Xie Q and Li X and Xu M and Zhou L},
  year = {2026},
  journal = {The Journal of pharmacy and pharmacology},
  doi = {10.1093/jpp/rgag139},
  url = {https://doi.org/10.1093/jpp/rgag139}
}

RIS

TY  - JOUR
TI  - Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling.
AU  - Zhang G
AU  - Wang X
AU  - Wang Y
AU  - Liu H
AU  - Xie Q
AU  - Li X
AU  - Xu M
AU  - Zhou L
PY  - 2026
JO  - The Journal of pharmacy and pharmacology
DO  - 10.1093/jpp/rgag139
UR  - https://doi.org/10.1093/jpp/rgag139
ER  -

APA

G, Z., X, W., Y, W., H, L., Q, X., X, L., M, X., & L, Z. (2026). Tiliroside reverses cisplatin resistance in non-small cell lung cancer via targeting IL-17RA to downregulate JAK2/STAT3 signaling.. The Journal of pharmacy and pharmacology. https://doi.org/10.1093/jpp/rgag139

Source records

pubmed · retrieved 2026-11-11T00:22:57.587Z